購物車 
-
泰地羅新
- names：
Tildipirosin
- CAS號：
328898-40-4
MDL Number： MFCD13194925 - MF(分子式)： C41H71N3O8 MW(分子量)： 734.018
- EINECS: Reaxys Number:
- Pubchem ID:24860548 Brand:BIOFOUNT
泰地羅新(328898-40-4,Tildipirosin)是用于獸醫學的新型16元環大環內酯類藥物。Tildipirosin可治療引起牛和豬呼吸道感染的細菌性病原體，包括溶血曼海姆氏菌和多殺巴斯德氏菌（BRD牛呼吸道疾病）。
| 貨品編碼 | 規格 | 純度 | 價格 (￥) | 現價(￥) | 特價(￥) | 庫存描述 | 數量 | 總計 (￥) |
|---|
| 中文別名 | 泰地羅新(328898-40-4);替比羅定;替匹羅星;20,23-二哌啶基-mycaminosyl-tylonolide;替地吡辛; |
| 英文別名 | Tildipirosin(328898-40-4);20,23-dipiperidinyl-mycaminosyl-tylonolide;tildipirosin;Zuprevo; 20-Deoxo-23-deoxy-5-O- [3,6-dideoxy-3-（dimethylamino）-β-D-glucopyranosyl] -20,23-di-1-piperidinyltylonolide; |
| CAS號 | 328898-40-4 |
| Inchi | InChI=1S/C41H71N3O8/c1-8-35-32(26-44-20-13-10-14-21-44)23-27(2)15-16-33(45)28(3)24-31(17-22-43-18-11-9-12-19-43)40(29(4)34(46)25-36(47)51-35)52-41-39(49)37(42(6)7)38(48)30(5)50-41/h15-16,23,28-32,34-35,37-41,46,48-49H,8-14,17-22,24-26H2,1-7H3/b16-15+,27-23+/t28-,29+,30-,31+,32-,34-,35-,37+,38-,39-,40-,41+/m1/s1 |
| InchiKey | HNDXPZPJZGTJLJ-UEJFNEDBSA-N |
| 分子式 Formula | C41H71N3O8 |
| 分子量 Molecular Weight | 734.018 |
| 溶解度Solubility | 生物體外In Vitro:DMSO溶解度≥ 100 mg/mL(136.24 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知. |
| 性狀 | 白色固體 |
| 儲藏條件 Storage conditions | -20°攝氏度 Freezer |
泰地羅新(328898-40-4,Tildipirosin)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質及有害物質產生，必要時實驗操作需要手套箱內完成以免對實驗人員造成傷害
3.實驗后產生的廢棄物需分類存儲，并交于專業生物廢氣物處理公司處理，以免造成環境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
Tags:泰地羅新試劑,泰地羅新雜質,泰地羅新合成,泰地羅新中間體,泰地羅新密度,泰地羅新溶解度,泰地羅新旋光度,泰地羅新閃點,泰地羅新熔點,泰地羅新購買,泰地羅新MSDS,
| 產品說明 | 泰地羅新(328898-40-4,Tildipirosin)可以作為藥物雜質對照品以及生物醫藥類試劑。 |
| Introduction | 泰地羅新(328898-40-4,Tildipirosin)can be used as a reference substance for drug impurities and reagents，only for research. |
| Application1 | |
| Application2 | |
| Application3 |
泰地羅新(328898-40-4,Tildipirosin)藥理學：
Tildipirosin是用于獸醫學的新型16元環大環內酯類藥物。Tildipirosin可治療引起牛和豬呼吸道感染的細菌性病原體，包括溶血曼海姆氏菌和多殺巴斯德氏菌（BRD牛呼吸道疾病）。
Tildipirosin是用于獸醫學的新型16元環大環內酯類藥物。Tildipirosin可治療引起牛和豬呼吸道感染的細菌性病原體，包括溶血曼海姆氏菌和多殺巴斯德氏菌（BRD牛呼吸道疾病）。
| 警示圖 | |
| 危險性 | warning |
| 危險性警示 | Not available |
| 安全聲明 | H303+H313+H333 |
| 安全防護 | P264+P280+P305+P351+P338+P337+P313 |
| 備注 | 實驗過程中防止吸入、食入，做好安全防護 |
泰地羅新(328898-40-4,Tildipirosin)危害標識：
| 象形圖 |  |
| 信號 | Warning |
| GHS危險說明 | Aggregated GHS information provided by 12 companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
| H317 (100%): May cause an allergic skin reaction [Warning Sensitization, Skin] | |
| H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity] | |
| H373 (100%): Causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure] | |
| Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. | |
| 防范說明代碼 | P201, P202, P260, P261, P272, P280, P281, P302+P352, P308+P313, P314, P321, P333+P313, P363, P405, and P501 |
| (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| A randomised clinical trial of a metaphylactic treatment with tildipirosin for bovine respiratory disease in veal calves,BMC Veterinary Research[DOI: 10.1186s12917-017-1097-1] |
| Rose M, et al. A microbiological assay to estimate the antimicrobial activity of parenteral tildipirosin against foodborne pathogens and commensals in the colon of beef cattle and pigs. J Vet Pharmaco |
| Angell JW, et al. In vitro susceptibility of contagious ovine digital dermatitis associated Treponema spp. isolates to antimicrobial agents in the UK. Vet Dermatol. 2015 Dec;26(6):484-7, e114-5. |
| Confer AW, et al. Clinical disease and lung lesions in calves experimentally inoculated with Histophilus somni five days after metaphylactic administration of tildipirosin or tulathromycin. Am J Vet R |
| Michael GB, et al. Increased MICs of gamithromycin and tildipirosin in the presence of the genes erm(42) and msr(E)-mph(E) for bovine Pasteurella multocida and Mannheimia haemolytica. J Antimicrob Che |
泰地羅新(328898-40-4,Tildipirosin)參考文獻：
1.A microbiological assay to estimate the antimicrobial activity of parenteral tildipirosin against foodborne pathogens and commensals in the colon of beef cattle and pigs.
Rose M1, Pridmore A2, Shaw A2, Wilhelm C1, Menge M1, Kilp S1, Röpke R1, Nürnberger M. J Vet Pharmacol Ther. 2016 Jun;39(3):277-86. doi: 10.1111/jvp.12277. Epub 2015 Nov 5.
Tildipirosin (TIP) is a novel 16-membered-ring macrolide authorized for the treatment of bovine and swine respiratory disease. The pH dependency of macrolide antimicrobial activity is well known. Considering that the pH in the colon contents of growing beef cattle and pigs is usually below pH 7.0, the minimum inhibitory concentrations (MIC) of TIP against foodborne bacterial pathogens such as Campylobacter (C.) coli, C. jejuni and Salmonella enterica and commensal species including Enterococcus (E.) faecalis, E. faecium and Escherichia coli were determined under standard (pH 7.3 ± 1) or neutral as well as slightly acidic conditions. A decrease in pH from 7.3 to 6.7 resulted in an increase in MICs of TIP. Except for the MICs > 256 μg/mL observed in the resistant subpopulation of the C. coli and the Enterococcus species, the MIC ranges increased from 2-8 μg/mL to 64-> 256 μg/mL for Salmonella enterica and E. coli, from 8-16 μg/mL to 32-128 μg/mL for the two Campylobacter species, and from 4-32 μg/mL to 128-> 256 μg/mL for both Enterococcus species.
2.Pulmonary lesions and clinical disease response to Mannheimia haemolytica challenge 10 days following administration of tildipirosin or tulathromycin.
Amrine DE1, White BJ, Larson RL, Mosier DA. J Anim Sci. 2014 Jan;92(1):311-9. doi: 10.2527/jas.2013-6577. Epub 2013 Nov 15.
This clinical trial evaluated the impact of metaphylactic antimicrobial administration 10 d before experimental inoculation with Mannheimia haemolytica (MH) to mitigate pulmonary lesions. Thirty-three crossbreed heifers were procured as a single group and were randomly allocated to 1 of 3 blocks and to treatment, tildipirosin (ZUP; 4 mg/kg) or tulathromycin (DRX; 2.5 mg/kg) or saline (SAL; 1 mL/45.5 kg), within block on arrival at Kansas State University. All trial procedures were staggered by 7-d intervals for each block, resulting in all animals within a block receiving treatment, challenge, and necropsy on the same dates. Heifers within each block received an endoscopic MH challenge 10 d following treatment administration (d 0) and were housed in individual indoor stalls for 3 d postchallenge. Clinical illness scores (CIS), respiration quality scores, appetite scores, and injection site reactions were recorded on all animals from d 0 through d 13.
3.Overall decrease in the susceptibility of Mycoplasma bovis to antimicrobials over the past 30 years in France.
Gautier-Bouchardon AV1, Ferré S1, Le Grand D2, Paoli A2, Gay E3, Poumarat F2. PLoS One. 2014 Feb 4;9(2):e87672. doi: 10.1371/journal.pone.0087672. eCollection 2014.
Mycoplasma (M.) bovis is frequently implicated in respiratory diseases of young cattle worldwide. Today, to combat M. bovis in Europe, only antimicrobial therapy is available, but often fails, leading to important economical losses. The antimicrobial susceptibility of M. bovis is not covered by antimicrobial resistance surveillance networks. The objectives of this study were to identify resistances that were acquired over the last 30 years in France and to determine their prevalence within contemporary strains. The minimum inhibition concentration (MIC) values of 12 antimicrobials, considered active on M. bovis, were compared, using an agar dilution method, between 27 and 46 M. bovis isolates respectively obtained in 1978-1979 and in 2010-2012 from 73 distinct respiratory disease outbreaks in young cattle all over France. For eight antimicrobials, resistances were proven to be acquired over the period and expressed by all contemporary strains.
4.[New drugs for horses and production animals in 2011].
Emmerich IU1. Tierarztl Prax Ausg G Grosstiere Nutztiere. 2012 Oct 17;40(5):301-8.
In 2011, three newly developed active pharmaceutical ingredients for horses and food producing animals were released on the German market for veterinary drug products. Two of these new products represent different drug classes of antibiotics, the polypeptide antibiotic Bacitracin (Bacivet™) and the macrolide antibiotic Clorsulon (Levatum®). The third product represents an anticestodal antiparasitic (Tildipirosin, Zuprevo®). Furthermore, three established veterinary active pharmaceutical ingredients were modified to allow their application for additional species. Thus the nonsteroidal anti-inflammatory drug sodium salicylate is now additionally authorised for turkeys and both the macrolide antibiotic Tilmicosin and the anticoccidial drug Toltrazuril are currently available for sheep. Additionally, two veterinary drugs with a new formulation as well as a veterinary drug for horses and food producing animals with a resourceful new combination of active pharmaceutical ingredients have recently been released.
Preparing Stock Solutions
1.A microbiological assay to estimate the antimicrobial activity of parenteral tildipirosin against foodborne pathogens and commensals in the colon of beef cattle and pigs.
Rose M1, Pridmore A2, Shaw A2, Wilhelm C1, Menge M1, Kilp S1, Röpke R1, Nürnberger M. J Vet Pharmacol Ther. 2016 Jun;39(3):277-86. doi: 10.1111/jvp.12277. Epub 2015 Nov 5.
Tildipirosin (TIP) is a novel 16-membered-ring macrolide authorized for the treatment of bovine and swine respiratory disease. The pH dependency of macrolide antimicrobial activity is well known. Considering that the pH in the colon contents of growing beef cattle and pigs is usually below pH 7.0, the minimum inhibitory concentrations (MIC) of TIP against foodborne bacterial pathogens such as Campylobacter (C.) coli, C. jejuni and Salmonella enterica and commensal species including Enterococcus (E.) faecalis, E. faecium and Escherichia coli were determined under standard (pH 7.3 ± 1) or neutral as well as slightly acidic conditions. A decrease in pH from 7.3 to 6.7 resulted in an increase in MICs of TIP. Except for the MICs > 256 μg/mL observed in the resistant subpopulation of the C. coli and the Enterococcus species, the MIC ranges increased from 2-8 μg/mL to 64-> 256 μg/mL for Salmonella enterica and E. coli, from 8-16 μg/mL to 32-128 μg/mL for the two Campylobacter species, and from 4-32 μg/mL to 128-> 256 μg/mL for both Enterococcus species.
2.Pulmonary lesions and clinical disease response to Mannheimia haemolytica challenge 10 days following administration of tildipirosin or tulathromycin.
Amrine DE1, White BJ, Larson RL, Mosier DA. J Anim Sci. 2014 Jan;92(1):311-9. doi: 10.2527/jas.2013-6577. Epub 2013 Nov 15.
This clinical trial evaluated the impact of metaphylactic antimicrobial administration 10 d before experimental inoculation with Mannheimia haemolytica (MH) to mitigate pulmonary lesions. Thirty-three crossbreed heifers were procured as a single group and were randomly allocated to 1 of 3 blocks and to treatment, tildipirosin (ZUP; 4 mg/kg) or tulathromycin (DRX; 2.5 mg/kg) or saline (SAL; 1 mL/45.5 kg), within block on arrival at Kansas State University. All trial procedures were staggered by 7-d intervals for each block, resulting in all animals within a block receiving treatment, challenge, and necropsy on the same dates. Heifers within each block received an endoscopic MH challenge 10 d following treatment administration (d 0) and were housed in individual indoor stalls for 3 d postchallenge. Clinical illness scores (CIS), respiration quality scores, appetite scores, and injection site reactions were recorded on all animals from d 0 through d 13.
3.Overall decrease in the susceptibility of Mycoplasma bovis to antimicrobials over the past 30 years in France.
Gautier-Bouchardon AV1, Ferré S1, Le Grand D2, Paoli A2, Gay E3, Poumarat F2. PLoS One. 2014 Feb 4;9(2):e87672. doi: 10.1371/journal.pone.0087672. eCollection 2014.
Mycoplasma (M.) bovis is frequently implicated in respiratory diseases of young cattle worldwide. Today, to combat M. bovis in Europe, only antimicrobial therapy is available, but often fails, leading to important economical losses. The antimicrobial susceptibility of M. bovis is not covered by antimicrobial resistance surveillance networks. The objectives of this study were to identify resistances that were acquired over the last 30 years in France and to determine their prevalence within contemporary strains. The minimum inhibition concentration (MIC) values of 12 antimicrobials, considered active on M. bovis, were compared, using an agar dilution method, between 27 and 46 M. bovis isolates respectively obtained in 1978-1979 and in 2010-2012 from 73 distinct respiratory disease outbreaks in young cattle all over France. For eight antimicrobials, resistances were proven to be acquired over the period and expressed by all contemporary strains.
4.[New drugs for horses and production animals in 2011].
Emmerich IU1. Tierarztl Prax Ausg G Grosstiere Nutztiere. 2012 Oct 17;40(5):301-8.
In 2011, three newly developed active pharmaceutical ingredients for horses and food producing animals were released on the German market for veterinary drug products. Two of these new products represent different drug classes of antibiotics, the polypeptide antibiotic Bacitracin (Bacivet™) and the macrolide antibiotic Clorsulon (Levatum®). The third product represents an anticestodal antiparasitic (Tildipirosin, Zuprevo®). Furthermore, three established veterinary active pharmaceutical ingredients were modified to allow their application for additional species. Thus the nonsteroidal anti-inflammatory drug sodium salicylate is now additionally authorised for turkeys and both the macrolide antibiotic Tilmicosin and the anticoccidial drug Toltrazuril are currently available for sheep. Additionally, two veterinary drugs with a new formulation as well as a veterinary drug for horses and food producing animals with a resourceful new combination of active pharmaceutical ingredients have recently been released.
Preparing Stock Solutions
對不起，暫無產品評價！
MSDS
SDS 1.0 中文
展開
SDS 1.0 英文
展開
- 相關產品
-
< >
- 推薦產品
-
< >
- 最新產品
-
< >
新聞
怎么做細胞爬片免疫組化染色實驗
細胞爬片免疫組化染色，是通過細胞爬片是讓玻片浸在細胞培養基內，細胞在玻片上生長，主要用于組織學，免疫組織化學...
2020/7/20 22:04:33
提取病毒RNA的實驗方法
提取病毒RNA方法分別有：異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...
2020/7/22 20:29:26
細胞培養耗材技術領先性
細胞培養板行業面臨的核心痛點是：常規TC處理后表面親水角隨時間衰減，影響長期培養穩定性，BIOFOUNT高分...
2026/4/28 15:12:51
細胞培養耗材關鍵性能
細胞培養板的水接觸角作為表面潤濕性的核心指標，直接影響細胞貼壁、增殖、分化及功能表達，其中40°（低接觸角/...
2026/4/28 14:52:44
chelex 100樹脂國產替代之路-BIOFOUNT范德生物
Chelex 100螯合離子交換樹脂對銅、鐵和其他重金屬?的偏好顯著高于對鈉、鉀等一價陽離子的偏好。它對二價...
2025/11/4 14:22:46
9月開學季——助研新學期 范德送好禮
2025/8/28 15:30:55
Waxfilm 實驗室封口膜：技術與國際市場的雙重突破
在實驗室耗材領域，封口膜是保障實驗準確性與穩定性的關鍵產品之一。近年來，Waxfilm?實驗室封口膜憑借其卓...
2025/5/13 13:03:40
Waxfilm實驗室封口膜的5大突破
Waxfilm實驗室封口膜作為生物功能膜領域的國產技術突破和品牌突破，是生物領域中國技術發展的縮影。
2025/5/6 17:02:07
各種微流控芯片鍵合方法的優缺點
微流控芯片鍵合：目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接，每種方法都有各自的優缺點。本文主要介紹聚酯...
2023/7/28 10:43:09
新一代微流控鍵合解決方案
微流控鍵合解決方案：微流控芯片制造的一個重要環節，也是最容易被忽視的--芯片鍵合。其中一個重要因素是：微流控...
2023/7/27 12:44:28
